BCAL DIAGNOSTICS ORD
BCAL Diagnostics on Track for Australian Launch of Aventect Pancreatic and Ovarian Cancer Tests
BCAL Diagnostics (ASX: BDX) is on track to launch the cutting-edge Avantect pancreatic and ovarian cancer tests onto the Australian market in the new year.
ASX Investment Opportunities on Show in Singapore During Grand Prix
All roads will lead to Singapore in early October with the important Spark Plus Aussie Equities Day investment show being staged in the lead-up to the local grand prix motoring event. The 2025 Spark Plus Aussie Equities Day is the 4th installment of their flagship event which aims to introduce a range of Australian companies to […]
BCAL Diagnostics launches groundbreaking blood test to aid early detection of breast cancer
BCAL Diagnostics (ASX: BDX) has launched a first-in-class blood test known as BREASTEST plus to address the challenge of high breast density, which can impact standard-of-care breast cancer screening practices. The company designed the lipid test for use alongside traditional mammogram imaging and it has been validated to meet the challenge of high breast density, […]
Market wrap: local factors push Australian stocks higher
While international influences such as the surprise jump in US bond yields had a big impact on the Australian share market overall, local factors also played a big part in some significant price volatility in many individual shares. By the close of trade on Friday the ASX 200 managed to reverse an earlier fall to […]
